Pfizer Inc. (PFE) announced that it would give scientists at Washington University School of Medicine in St. Louis unprecedented access to information regarding more than 500 pharmaceuticals and pharmaceutical candidates in a partnership that focuses on discovering new uses for existing compounds.
Under the five-year agreement announced , Pfizer will provide $22.5 million to Washington University and give its scientists access to research data on a large array of Pfizer pharmaceutical candidates that are currently or were formerly in clinical testing.
Pfizer said that the agreement builds on the long history of collaboration between the two organizations and brings together scientists from Pfizer and Washington University to jointly propose, design and carry out research on those compounds across a broad range of disease areas in which the University has internationally renowned scientific expertise, such as Alzheimer's, cancer, diabetes and related metabolic disorders, and asthma and chronic obstructive pulmonary disease.
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org